Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	G protein-coupled neurotensin receptor activity	NTSR2 NTSR1	2.98e-06	2	35	2	GO:0016492
GeneOntologyMolecularFunction	deaminase binding	HNRNPCL1 HNRNPCL2	1.79e-05	4	35	2	GO:1990827
GeneOntologyMolecularFunction	metallocarboxypeptidase activity	CPA4 CPA6 AGBL2	2.14e-05	31	35	3	GO:0004181
GeneOntologyMolecularFunction	carboxypeptidase activity	CPA4 CPA6 AGBL2	8.60e-05	49	35	3	GO:0004180
GeneOntologyMolecularFunction	metalloexopeptidase activity	CPA4 CPA6 AGBL2	2.49e-04	70	35	3	GO:0008235
GeneOntologyMolecularFunction	arylsulfatase activity	ARSF ARSG	2.68e-04	14	35	2	GO:0004065
GeneOntologyMolecularFunction	N6-methyladenosine-containing RNA reader activity	HNRNPCL1 HNRNPCL2	3.09e-04	15	35	2	GO:1990247
GeneOntologyMolecularFunction	sulfuric ester hydrolase activity	ARSF ARSG	3.99e-04	17	35	2	GO:0008484
GeneOntologyMolecularFunction	protein-RNA adaptor activity	HNRNPCL1 HNRNPCL2	8.04e-04	24	35	2	GO:0140517
GeneOntologyMolecularFunction	telomerase RNA binding	HNRNPCL1 HNRNPCL2	8.73e-04	25	35	2	GO:0070034
GeneOntologyMolecularFunction	exopeptidase activity	CPA4 CPA6 AGBL2	9.36e-04	110	35	3	GO:0008238
GeneOntologyMolecularFunction	poly(U) RNA binding	HNRNPCL1 HNRNPCL2	1.62e-03	34	35	2	GO:0008266
GeneOntologyMolecularFunction	poly-pyrimidine tract binding	HNRNPCL1 HNRNPCL2	2.12e-03	39	35	2	GO:0008187
GeneOntologyMolecularFunction	neuropeptide receptor activity	NTSR2 NTSR1	3.89e-03	53	35	2	GO:0008188
GeneOntologyMolecularFunction	transition metal ion binding	CPA4 CPA6 AGBL2 SC5D MYCBP2 RBM4B P3H2	4.03e-03	1189	35	7	GO:0046914
GeneOntologyMolecularFunction	metallopeptidase activity	CPA4 CPA6 AGBL2	5.12e-03	200	35	3	GO:0008237
GeneOntologyMolecularFunction	NADP binding	HMGCR HSD11B1	5.28e-03	62	35	2	GO:0050661
GeneOntologyMolecularFunction	ribonucleoprotein complex binding	NAA10 HNRNPCL1 HNRNPCL2	5.55e-03	206	35	3	GO:0043021
GeneOntologyBiologicalProcess	negative regulation of mRNA modification	HNRNPCL1 HNRNPCL2	3.94e-05	6	34	2	GO:0090367
GeneOntologyBiologicalProcess	negative regulation of DNA biosynthetic process	HNRNPCL1 HNRNPCL2 MEN1	4.83e-05	43	34	3	GO:2000279
GeneOntologyBiologicalProcess	alcohol metabolic process	HMGCR CHKA DYSF SC5D DGAT1 NTSR1	5.13e-05	412	34	6	GO:0006066
GeneOntologyBiologicalProcess	regulation of mRNA modification	HNRNPCL1 HNRNPCL2	5.51e-05	7	34	2	GO:0090365
GeneOntologyCellularComponent	nucleoplasmic periphery of the nuclear pore complex	HNRNPCL1 HNRNPCL2	4.31e-05	6	36	2	GO:1990826
GeneOntologyCellularComponent	telomerase holoenzyme complex	HNRNPCL1 HNRNPCL2	8.44e-04	25	36	2	GO:0005697
GeneOntologyCellularComponent	pronucleus	HNRNPCL1 HNRNPCL2	1.06e-03	28	36	2	GO:0045120
Domain	NT_rcpt	NTSR2 NTSR1	3.82e-06	2	37	2	IPR003984
Domain	CARBOXYPEPT_ZN_2	CPA4 CPA6 AGBL2	6.79e-06	19	37	3	PS00133
Domain	CARBOXYPEPT_ZN_1	CPA4 CPA6 AGBL2	7.97e-06	20	37	3	PS00132
Domain	Peptidase_M14	CPA4 CPA6 AGBL2	1.23e-05	23	37	3	PF00246
Domain	Peptidase_M14	CPA4 CPA6 AGBL2	1.23e-05	23	37	3	IPR000834
Domain	hnRNP_C	HNRNPCL1 HNRNPCL2	5.70e-05	6	37	2	IPR017347
Domain	-	CPA4 CPA6	1.06e-04	8	37	2	3.30.70.340
Domain	Propep_M14	CPA4 CPA6	1.06e-04	8	37	2	PF02244
Domain	M14A_act_pep	CPA4 CPA6	1.06e-04	8	37	2	IPR003146
Domain	Sulfatase_CS	ARSF ARSG	4.50e-04	16	37	2	IPR024607
Domain	SULFATASE_1	ARSF ARSG	5.10e-04	17	37	2	PS00523
Domain	Propept_inh	CPA4 CPA6	5.10e-04	17	37	2	IPR009020
Domain	SULFATASE_2	ARSF ARSG	5.10e-04	17	37	2	PS00149
Domain	Sulfatase	ARSF ARSG	5.73e-04	18	37	2	PF00884
Domain	Sulfatase_N	ARSF ARSG	5.73e-04	18	37	2	IPR000917
Domain	Zn_pept	CPA4 CPA6	5.73e-04	18	37	2	SM00631
Domain	RRM_1	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	7.40e-04	208	37	4	PF00076
Domain	RRM	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	8.67e-04	217	37	4	SM00360
Domain	RRM_dom	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	1.02e-03	227	37	4	IPR000504
Domain	RRM	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	1.08e-03	230	37	4	PS50102
Domain	-	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	1.34e-03	244	37	4	3.30.70.330
Domain	Nucleotide-bd_a/b_plait	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	1.64e-03	258	37	4	IPR012677
Domain	Alkaline_phosphatase_core	ARSF ARSG	1.71e-03	31	37	2	IPR017850
Domain	Alkaline_Pase-like_a/b/a	ARSF ARSG	1.71e-03	31	37	2	IPR017849
Domain	-	ARSF ARSG	1.71e-03	31	37	2	3.40.720.10
Domain	zf-RING_2	ZNRF3 MYCBP2	4.76e-03	52	37	2	PF13639
Domain	GPCR_Rhodpsn_7TM	NTSR2 OR2T10 TRHR OR2T27 NTSR1	9.86e-03	670	37	5	IPR017452
Domain	7tm_1	NTSR2 OR2T10 TRHR OR2T27 NTSR1	1.03e-02	677	37	5	PF00001
Domain	G_PROTEIN_RECEP_F1_1	NTSR2 OR2T10 TRHR OR2T27 NTSR1	1.08e-02	685	37	5	PS00237
Domain	G_PROTEIN_RECEP_F1_2	NTSR2 OR2T10 TRHR OR2T27 NTSR1	1.12e-02	691	37	5	PS50262
Domain	GPCR_Rhodpsn	NTSR2 OR2T10 TRHR OR2T27 NTSR1	1.12e-02	692	37	5	IPR000276
Pathway	WP_ENTEROCYTE_CHOLESTEROL_METABOLISM	HMGCR SC5D DGAT1	5.34e-05	36	29	3	M48067
Pathway	REACTOME_THE_ACTIVATION_OF_ARYLSULFATASES	ARSF ARSG	3.14e-04	13	29	2	M663
Pathway	WP_GPCRS_PEPTIDE	NTSR2 TRHR NTSR1	3.91e-04	70	29	3	MM15959
Pathway	WP_CHOLESTEROL_BIOSYNTHESIS	HMGCR SC5D	4.22e-04	15	29	2	MM15921
Pathway	WP_CHOLESTEROL_BIOSYNTHESIS_PATHWAY	HMGCR SC5D	4.22e-04	15	29	2	M39608
Pathway	WP_CHOLESTEROL_METABOLISM	HMGCR SC5D DGAT1	4.24e-04	72	29	3	M46457
Pathway	WP_PEPTIDE_GPCRS	NTSR2 TRHR NTSR1	4.78e-04	75	29	3	M39696
Pathway	WP_CHOLESTEROL_SYNTHESIS_DISORDERS	HMGCR SC5D	6.13e-04	18	29	2	M45528
Pathway	WP_STATIN_PATHWAY	HMGCR DGAT1	6.84e-04	19	29	2	MM15868
Pathway	REACTOME_METABOLISM_OF_LIPIDS	HMGCR HSD11B1 CHKA ARSF SC5D ARSG DGAT1	6.91e-04	757	29	7	M27451
Pathway	REACTOME_RHOBTB2_GTPASE_CYCLE	HNRNPCL1 HNRNPCL2	1.19e-03	25	29	2	MM15606
Pathway	REACTOME_RHOBTB1_GTPASE_CYCLE	HNRNPCL1 HNRNPCL2	1.19e-03	25	29	2	MM15608
Pathway	REACTOME_CHOLESTEROL_BIOSYNTHESIS	HMGCR SC5D	1.39e-03	27	29	2	MM14735
Pathway	REACTOME_CHOLESTEROL_BIOSYNTHESIS	HMGCR SC5D	1.39e-03	27	29	2	M16227
Pathway	REACTOME_METABOLISM_OF_LIPIDS	HMGCR HSD11B1 CHKA SC5D ARSG DGAT1	1.41e-03	620	29	6	MM15193
Pathway	WP_STATIN_INHIBITION_OF_CHOLESTEROL_PRODUCTION	HMGCR DGAT1	1.83e-03	31	29	2	M39514
Pathway	WP_MRNA_PROCESSING	HNRNPCL1 DDX24 RBM4B HNRNPCL2 ESRP1	2.06e-03	451	29	5	MM15946
Pathway	REACTOME_METABOLISM_OF_STEROIDS	HMGCR HSD11B1 SC5D	2.15e-03	126	29	3	MM15553
Pathway	REACTOME_RHOBTB_GTPASE_CYCLE	HNRNPCL1 HNRNPCL2	2.60e-03	37	29	2	MM15683
Pathway	REACTOME_GLYCOSPHINGOLIPID_CATABOLISM	ARSF ARSG	2.89e-03	39	29	2	M48042
Pathway	REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP	HMGCR SC5D	3.34e-03	42	29	2	M27172
Pathway	REACTOME_METABOLISM_OF_STEROIDS	HMGCR HSD11B1 SC5D	3.79e-03	154	29	3	M27832
Pathway	WP_CHOLESTEROL_METABOLISM_WITH_BLOCH_AND_KANDUTSCHRUSSELL_PATHWAYS	HMGCR SC5D	4.17e-03	47	29	2	M39853
Pathway	KEGG_MEDICUS_REFERENCE_GPCR_PLCB_ITPR_SIGNALING_PATHWAY	TRHR NTSR1	4.71e-03	50	29	2	M47951
Pathway	WP_CHOLESTEROL_METABOLISM_WITH_BLOCH_AND_KANDUTSCHRUSSELL_PATHWAYS	HMGCR SC5D	5.08e-03	52	29	2	MM15920
Pubmed	Intermolecular cross-talk between NTR1 and NTR2 neurotensin receptor promotes intracellular sequestration and functional inhibition of NTR1 receptors.	NTSR2 NTSR1	1.10e-06	2	37	2	19968961
Pubmed	NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain.	NTSR2 NTSR1	1.10e-06	2	37	2	22504145
Pubmed	Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.	NTSR2 NTSR1	1.10e-06	2	37	2	20211191
Pubmed	Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception.	NTSR2 NTSR1	1.10e-06	2	37	2	14725975
Pubmed	Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice.	NTSR2 NTSR1	1.10e-06	2	37	2	15030383
Pubmed	Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells.	NTSR2 NTSR1	1.10e-06	2	37	2	26298774
Pubmed	Characterisation of the Expression of Neurotensin and Its Receptors in Human Colorectal Cancer and Its Clinical Implications.	NTSR2 NTSR1	3.30e-06	3	37	2	32764278
Pubmed	Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells.	NTSR2 NTSR1	3.30e-06	3	37	2	28498396
Pubmed	Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes.	NTSR2 NTSR1	3.30e-06	3	37	2	23109725
Pubmed	Identification of Neurotensin Receptor Expressing Cells in the Ventral Tegmental Area across the Lifespan.	NTSR2 NTSR1	3.30e-06	3	37	2	29464190
Pubmed	Neurotensin counteracts apoptosis in breast cancer cells.	NTSR2 NTSR1	3.30e-06	3	37	2	12150975
Pubmed	Neurotensinergic Excitation of Dentate Gyrus Granule Cells via Gαq-Coupled Inhibition of TASK-3 Channels.	NTSR2 NTSR1	3.30e-06	3	37	2	25405940
Pubmed	Neurotensin Receptor-1 Identifies a Subset of Ventral Tegmental Dopamine Neurons that Coordinates Energy Balance.	NTSR2 NTSR1	3.30e-06	3	37	2	28834751
Pubmed	Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer.	NTSR2 NTSR1	3.30e-06	3	37	2	20048080
Pubmed	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.	NTSR2 NTSR1	6.60e-06	4	37	2	30770901
Pubmed	N6-methylation of RNA-bound adenosine regulator HNRNPC promotes vascular endothelial dysfunction in type 2 diabetes mellitus by activating the PSEN1-mediated Notch pathway.	HNRNPCL1 HNRNPCL2	6.60e-06	4	37	2	36681355
Pubmed	Genetic analysis of the hypothalamic neurotensin system.	NTSR2 NTSR1	6.60e-06	4	37	2	16123747
Pubmed	Expression of neurotensin and its receptors in pituitary adenomas.	NTSR2 NTSR1	6.60e-06	4	37	2	18624930
Pubmed	The splicing factor hnRNP C regulates expression of co-stimulatory molecules CD80 and CD40 in dendritic cells.	HNRNPCL1 HNRNPCL2	6.60e-06	4	37	2	23831410
Pubmed	hnRNP C is required for postimplantation mouse development but Is dispensable for cell viability.	HNRNPCL1 HNRNPCL2	6.60e-06	4	37	2	10805751
Pubmed	hnRNPC induces isoform shifts in miR-21-5p leading to cancer development.	HNRNPCL1 HNRNPCL2	6.60e-06	4	37	2	35729324
Pubmed	Neurotensin and neurotensin receptors.	NTSR2 NTSR1	6.60e-06	4	37	2	10390649
Pubmed	Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis.	NTSR2 NTSR1	6.60e-06	4	37	2	18376408
Pubmed	Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain.	NTSR2 NTSR1	6.60e-06	4	37	2	8795617
Pubmed	A novel form of neurotensin post-translationally modified by arginylation.	NTSR2 NTSR1	6.60e-06	4	37	2	16087676
Pubmed	Endogenous CNS expression of neurotensin and neurotensin receptors is altered during the postpartum period in outbred mice.	NTSR2 NTSR1	6.60e-06	4	37	2	24416154
Pubmed	Heterogeneous nuclear ribonucleoprotein C1 may control miR-30d levels in endometrial exosomes affecting early embryo implantation.	HNRNPCL1 HNRNPCL2	1.10e-05	5	37	2	29846695
Pubmed	Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain.	HMGCR DGAT1	1.10e-05	5	37	2	14722362
Pubmed	Characterization of two nuclear proteins that interact with cytochrome P-450 1A2 mRNA. Regulation of RNA binding and possible role in the expression of the Cyp1a2 gene.	HNRNPCL1 HNRNPCL2	1.10e-05	5	37	2	9128719
Pubmed	Evaluating the role of hnRNP-C and FMRP in the cAMP-induced APP metabolism.	HNRNPCL1 HNRNPCL2	1.10e-05	5	37	2	25809670
Pubmed	A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis.	CHKA DYSF	1.10e-05	5	37	2	16371353
Pubmed	Protein kinase CK1alpha regulates mRNA binding by heterogeneous nuclear ribonucleoprotein C in response to physiologic levels of hydrogen peroxide.	HNRNPCL1 HNRNPCL2	1.65e-05	6	37	2	15687492
Pubmed	Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease.	HNRNPCL1 HNRNPCL2	1.65e-05	6	37	2	26048669
Pubmed	Selective disruption of genes expressed in totipotent embryonal stem cells.	HNRNPCL1 HNRNPCL2	1.65e-05	6	37	2	1317320
Pubmed	Concomitant transitory up-regulation of X-linked inhibitor of apoptosis protein (XIAP) and the heterogeneous nuclear ribonucleoprotein C1-C2 in surviving cells during neuronal apoptosis.	HNRNPCL1 HNRNPCL2	1.65e-05	6	37	2	18363099
Pubmed	Age-related expression analysis of mouse liver nuclear protein binding to 3'-untranslated region of Period2 gene.	HNRNPCL1 HNRNPCL2	2.30e-05	7	37	2	25846207
Pubmed	Small subfamily of olfactory receptor genes: structural features, expression pattern and genomic organization.	HNRNPCL1 HNRNPCL2	3.95e-05	9	37	2	10452948
Pubmed	Genetic complexity of an obesity QTL ( Fob3) revealed by detailed genetic mapping.	TRHR DGAT1	3.95e-05	9	37	2	15181539
Pubmed	Interaction between nucleosome assembly protein 1-like family members.	HNRNPCL1 HNRNPCL2	7.22e-05	12	37	2	21333655
Pubmed	The biogenesis of the coiled body during early mouse development.	HNRNPCL1 HNRNPCL2	7.22e-05	12	37	2	7768196
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	SAV1 HNRNPCL1 MYCBP2 RBM4B HNRNPCL2	1.24e-04	462	37	5	31138677
Pubmed	A method to identify cDNAs based on localization of green fluorescent protein fusion products.	HNRNPCL1 HNRNPCL2	1.48e-04	17	37	2	10716735
Pubmed	Identification of targets for calcium signaling through the copine family of proteins. Characterization of a coiled-coil copine-binding motif.	MYCBP2 KIAA1217	3.25e-04	25	37	2	12522145
Pubmed	Stage-specific changes in gene expression in acutely isolated mouse CNS progenitor cells.	HNRNPCL1 HNRNPCL2	3.52e-04	26	37	2	15890332
Pubmed	A genome-wide in situ hybridization map of RNA-binding proteins reveals anatomically restricted expression in the developing mouse brain.	HNRNPCL1 RBM4B HNRNPCL2 ESRP1	4.96e-04	347	37	4	16033648
Pubmed	A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal.	RBM4B KIAA1217 MEN1	5.07e-04	146	37	3	23892456
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	NAA10 HNRNPCL1 DYSF HNRNPCL2	5.87e-04	363	37	4	14691545
Pubmed	A compendium of expression patterns of cholesterol biosynthetic enzymes in the mouse embryo.	HMGCR SC5D	7.16e-04	37	37	2	26108225
Cytoband	1p36.21	HNRNPCL1 HNRNPCL2	1.20e-03	63	37	2	1p36.21
Cytoband	1q44	OR2T10 OR2T27	3.59e-03	110	37	2	1q44
Cytoband	8q24.3	DENND3 DGAT1	3.78e-03	113	37	2	8q24.3
Cytoband	11q13	RBM4B MEN1	4.11e-03	118	37	2	11q13
Cytoband	Ensembl 112 genes in cytogenetic band chr1q44	OR2T10 OR2T27	4.82e-03	128	37	2	chr1q44
Cytoband	Ensembl 112 genes in cytogenetic band chr11q13	CHKA RBM4B MEN1	5.82e-03	454	37	3	chr11q13
Cytoband	Ensembl 112 genes in cytogenetic band chr11p11	EXT2 AGBL2	6.81e-03	153	37	2	chr11p11
GeneFamily	Neurotensin receptors	NTSR2 NTSR1	1.55e-06	2	23	2	244
GeneFamily	Sulfatases	ARSF ARSG	2.34e-04	18	23	2	410
GeneFamily	Carboxypeptidases	CPA4 CPA6	3.20e-04	21	23	2	1321
GeneFamily	RNA binding motif containing	HNRNPCL1 RBM4B ESRP1	2.40e-03	213	23	3	725
GeneFamily	Olfactory receptors, family 2	OR2T10 OR2T27	8.99e-03	113	23	2	149
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N CHKA ZNF608 ZNRF3 KIAA1217 ESRP1	1.09e-08	190	37	6	8aea807a2bcf0b653b4de6202b6ecb0f0683cc2e
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA ZNRF3 P3H2 ESRP1	4.25e-07	184	37	5	ab2f06906fc7a9931dfa0864ef506832b07fb93e
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA ZNRF3 P3H2 ESRP1	4.48e-07	186	37	5	e83718fabb057100835d3357df407f283d23fe16
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA ZNRF3 P3H2 ESRP1	4.72e-07	188	37	5	4bdf8d49af0e9da349b16e3f012e1b0eec04cc4f
ToppCell	human_hepatoblastoma-Tumor_cells-T5\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	CPA6 ZNRF3 P3H2 KIAA1217 ESRP1	4.72e-07	188	37	5	b070a0667f1ee9b825b267b6c389b7c42fc436f9
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ZNF608 ZNRF3 P3H2 KIAA1217 ESRP1	5.11e-07	191	37	5	ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNRF3 P3H2 KIAA1217 ESRP1	5.11e-07	191	37	5	34cc997e4e5c727495f321e6807a84aa124da486
ToppCell	Children_(3_yrs)-Epithelial\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ZNF608 ZNRF3 P3H2 KIAA1217 ESRP1	5.11e-07	191	37	5	e432c6e1ae82dddf84314ce73d2b7a991630d905
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNRF3 P3H2 KIAA1217 ESRP1	5.24e-07	192	37	5	fb2f0e897228f808d9ff734ad05e9b49dc38fa50
ToppCell	Fetal_29-31_weeks-Epithelial\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N CHKA P3H2 KIAA1217 ESRP1	5.38e-07	193	37	5	a0ca3231992f14abcf1a6129573bace320e89d2a
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Epithelial-epithelial_progenitor_cell-Proximal_progenitor\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SI TC2N DGAT1 ESRP1	1.32e-05	175	37	4	6759d200a133034756de9cdf2d5daceca927aac9
ToppCell	LPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.44e-05	179	37	4	fd2cbee532e7b44113410dca82aec7db1a7fb69f
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.48e-05	180	37	4	b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCell	LPS_only-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HSD11B1 TC2N P3H2 ESRP1	1.51e-05	181	37	4	0513b9e6673ff7bf8e72ba123ca3794b65d10170
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.54e-05	182	37	4	17ed11a7ea366dd3106400511d5e628d3f1a9c3e
ToppCell	LPS_only-Epithelial_alveolar-AT_2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.57e-05	183	37	4	e972432dd4d1bd31bb0982f4df3061e5e152658f
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.61e-05	184	37	4	d0c212a8fbaad24597a84018442b25c61c17ea58
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.64e-05	185	37	4	fefaf227d89f680d6f3e91c4a94e26ab4d0dc6c3
ToppCell	LPS_only-Epithelial_alveolar\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.68e-05	186	37	4	e0a2ea4b46af742bc7c9b2072bb85e27d5c92712
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNF608 KIAA1217 ESRP1	1.68e-05	186	37	4	2ea5ff14861e5f91d0e6a5767c403a24045d715c
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA ZNRF3 ESRP1	1.68e-05	186	37	4	4e94158db52df41d71e67b02b9895a358eebee0f
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ZNF608 P3H2 DENND3 KIAA1217	1.71e-05	187	37	4	4ae7465174e0295d2c3b614b321a3b2f514dd22a
ToppCell	LPS-antiTNF-Epithelial_alveolar\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.71e-05	187	37	4	201ff693e4756ee3e44762885b3a303a77eb535b
ToppCell	LPS-IL1RA-Epithelial_alveolar\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.75e-05	188	37	4	6164d467b612767ceba15de34176bcc8e8c36ab8
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA P3H2 ESRP1	1.75e-05	188	37	4	43a0508d2524a5b310e89e9422843dcaab999bc3
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	ZNRF3 P3H2 KIAA1217 ESRP1	1.90e-05	192	37	4	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	wk_15-18-Epithelial-Airway_epithelial_progenitor-epi-stalk_late\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	TC2N ZNRF3 P3H2 ESRP1	2.14e-05	198	37	4	1851b7f4198b42c21c934e2fbda39dbd65e2625c
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNF608 KIAA1217 ESRP1	2.14e-05	198	37	4	6ba5e5970109a04ed968bac7ff099ae250c579dc
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNF608 KIAA1217 ESRP1	2.14e-05	198	37	4	5fc25b008a4d8d6bec83923a16f64dd9e1ff1f2d
ToppCell	Bronchial-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CHKA P3H2 KIAA1217 ESRP1	2.19e-05	199	37	4	5f7da3eab58ace6cddb3179a415cd839d5767958
ToppCell	Parenchymal-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CHKA P3H2 KIAA1217 ESRP1	2.19e-05	199	37	4	5cea0d9e261903e0eaad60c28a07dff72ce65027
ToppCell	LPS-antiTNF-Epithelial_alveolar-Mes-Like-AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N P3H2 ESRP1	1.52e-04	125	37	3	5626eb77e542fcc87cd1fdf65f8623f3249ff9db
ToppCell	facs-Marrow-B-cells-18m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPA6 HSD11B1 DYSF	2.97e-04	157	37	3	0673c7161c25feceee8f1e5fd237171576c42c6b
ToppCell	facs-Marrow-B-cells-18m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPA6 HSD11B1 DYSF	2.97e-04	157	37	3	d307d0b48af35e0e1af41ecd3ebf91be8fd29dc0
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	SAV1 HSD11B1 TC2N	3.08e-04	159	37	3	1472536eea61d4f13033efe42f128bae1614fa74
ToppCell	normal_Lymph_Node-Myeloid_cells-CD141+_DCs\|Myeloid_cells / Location, Cell class and cell subclass	AGBL2 DYSF ZNRF3	3.49e-04	166	37	3	6210a136efb99d70c2026b6454363f1bd2723558
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-6_VIP_PENK\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARSF ZNF608 NTSR1	3.68e-04	169	37	3	eb3b8e473192c4b8688f2f8da400116dd6fe193d
ToppCell	droplet-Liver-nan-3m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DYSF NEK5 P3H2	3.88e-04	172	37	3	1f335ccb92b22d0412954e8fc3af212f96410b67
ToppCell	metastatic_Brain-Fibroblasts-Undetermined\|Fibroblasts / Location, Cell class and cell subclass	HMGCR CHKA NEK5	3.88e-04	172	37	3	c3822ff7329c3ac38c68c5c38cd67c390682e2a6
ToppCell	droplet-Liver-nan-3m-Myeloid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DYSF NEK5 P3H2	3.88e-04	172	37	3	bb96c896d125e10b71e94e2bdad243899045af5c
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ZNF608 P3H2 KIAA1217	3.94e-04	173	37	3	b799c06a6a5754668e789f70c0c8bc1508568575
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	SAV1 HSD11B1 TC2N	3.94e-04	173	37	3	7e2149205e119cec4f5099c83c85d1e13470137a
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-5_VIP_KCNJ2\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARSF ZNF608 NTSR1	4.01e-04	174	37	3	fdadac1eaab2c4a67e4832f0901df22e893add6a
ToppCell	facs-Marrow-Granulocytes-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPA6 HSD11B1 DGAT1	4.22e-04	177	37	3	065bebd22031f143e90a407f952b444a3f8818c7
ToppCell	facs-Marrow-Granulocytes-3m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPA6 HSD11B1 DGAT1	4.22e-04	177	37	3	eb304f20aab075bd17aa3aef819386c0e1a235bd
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ZNF608 KIAA1217 ESRP1	4.29e-04	178	37	3	f5ed4a6e3eb8056b1be1fb311021710c95bdf888
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TC2N ZNF608 KIAA1217	4.36e-04	179	37	3	815b959ce8721c5ded70c0ca6e318dafc691746e
ToppCell	Control-Epithelial_alveolar-AT_1-AT1-AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	P3H2 DENND3 ESRP1	4.57e-04	182	37	3	a95956ce4adccb34cc0c47ebfa1878ce4617904e
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N P3H2 ESRP1	4.57e-04	182	37	3	1e2149b222a3e9f64841aed45288a6f29394e7b0
ToppCell	LPS_only-Epithelial_alveolar-AT_2-AT2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N P3H2 ESRP1	4.57e-04	182	37	3	d1a1feef318062f25493355d7beee8e5fb0e4206
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N DENND3 ESRP1	4.65e-04	183	37	3	274483009b309289e4cb84beedf6806430db6ff6
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N CHKA ESRP1	4.72e-04	184	37	3	7cc5796557379c3d1db078c1aeda40659c6e401c
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CPA6 P3H2 DENND3	4.72e-04	184	37	3	29c95b814a0b1ad8734ed68b77df29c08594e5ec
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like-ILC3\|lymph-node_spleen / Manually curated celltypes from each tissue	CPA6 CHKA KIAA1217	4.72e-04	184	37	3	479e60f76c191253e23699c9dd7ef7efc08c59ad
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Adult / Lineage, Cell type, age group and donor	ZNF608 KIAA1217 ESRP1	4.79e-04	185	37	3	673f0c688ae6984bc8027df2da335787924f4137
ToppCell	LPS_only-Epithelial_alveolar-AT_1-AT1-AT2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N P3H2 ESRP1	4.79e-04	185	37	3	68f428e169cfb77de970bdfdeea9b9f16f68d2ba
ToppCell	Control-Epithelial_alveolar-AT_2-Differentiating_AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ZNRF3 P3H2 ESRP1	4.79e-04	185	37	3	0d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCell	Control-Epithelial_alveolar\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	P3H2 DENND3 ESRP1	4.79e-04	185	37	3	3937e026add96a396122139daf8011cfbc60e75c
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ZNF608 KIAA1217 ESRP1	4.79e-04	185	37	3	98b8ee42b89d97e4c9db01740e0c193503c68f2c
ToppCell	Control-Epithelial_alveolar-AT_2-AT2_Progenitor\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CPA6 P3H2 ESRP1	4.79e-04	185	37	3	8ca1374501eca01d8468130b74d50abfd4329fbe
ToppCell	COVID-19-Epithelial_cells-Airway_club\|COVID-19 / group, cell type (main and fine annotations)	ZNF608 KIAA1217 ESRP1	4.79e-04	185	37	3	cfe6fd73d817e173fe803bc1683c291d9bcb8608
ToppCell	NS-critical-LOC-Epithelial-Basal\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CPA4 KIAA1217 ESRP1	4.87e-04	186	37	3	c28f62524637c7eb9c43c9ec38fb12dfec6f5566
ToppCell	droplet-Bladder-nan\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHKA MYCBP2 DDX24	4.95e-04	187	37	3	663991a8afe652e92363b64bcbd68c14d0307f0e
ToppCell	pdx-Tumor_cells-T5\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	CPA6 ZNRF3 P3H2	4.95e-04	187	37	3	7e376831a11ee72ed87abcdac631ca46ae29c250
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D175\|Adult / Lineage, Cell type, age group and donor	DYSF ZNF608 KIAA1217	4.95e-04	187	37	3	f3548817f2fded5978137bb252cb628ac199e4f6
ToppCell	PCW_10-12-Epithelial-Epithelial_proliferating-epi_proliferating1_(8)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	4.95e-04	187	37	3	c2940aec30b3c2c113f6a65126dc6f1969cf301e
ToppCell	PCW_10-12-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	4.95e-04	187	37	3	db2974e2e87ac9f1c2407a371d5ed89af09fc9b7
ToppCell	Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|World / Lineage, Cell type, age group and donor	ZNF608 KIAA1217 ESRP1	4.95e-04	187	37	3	81cc8435b2704a9a8287b3f54acaae0f11dd4ac7
ToppCell	PCW_13-14-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.02e-04	188	37	3	0d86044bc340e3efb90d0022dd299873639d831c
ToppCell	PCW_10-12-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.02e-04	188	37	3	beb2df2332a46cc81b10e8e29fc9829020111f03
ToppCell	PCW_10-12-Epithelial-Epithelial_neuroendo-epi_NE_progenitor_(7)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.02e-04	188	37	3	3cfba3addcc9058f4ec31ad96261f79988f551a0
ToppCell	COVID-19-Epithelial_cells\|COVID-19 / group, cell type (main and fine annotations)	P3H2 KIAA1217 ESRP1	5.02e-04	188	37	3	c9cdee6f8d42ee69f5fb335f25084603c511bd29
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.10e-04	189	37	3	7659c7bbd58ee959a159294fb8d17317bbcc5681
ToppCell	COVID-19-lung-Secretory\|lung / Disease (COVID-19 only), tissue and cell type	ZNF608 KIAA1217 ESRP1	5.10e-04	189	37	3	84d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25
ToppCell	PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_SFTPC^high_distal_(9)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.10e-04	189	37	3	5d9da836ce4308b8458bb3be3871a0aca734b6cd
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N P3H2 ESRP1	5.10e-04	189	37	3	5f883ef4cc0383142d538ae61f4fb40dfdb8ef18
ToppCell	LPS_only-Endothelial-Endothelial-Alv_Cap\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DYSF ZNF608 KIAA1217	5.18e-04	190	37	3	474cbbab8f3b0a6881fa6c92edb78e43999f9ab0
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_intermediate_(1)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.18e-04	190	37	3	c95032bb3ee2b3d40fdf48016acb46d6f78a48a6
ToppCell	PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.18e-04	190	37	3	625c08a0e5227efc46daa512fd579c3938ff76c7
ToppCell	PND07-Epithelial\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TC2N CHKA ESRP1	5.18e-04	190	37	3	e3a2c8b637f60c963520dffe99c526809d818cab
ToppCell	PCW_05-06-Epithelial-Epithelial_airway-epi_intermediate_(1)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.26e-04	191	37	3	72dbd2e0fabfca8d6f604df35277d3574739a0b3
ToppCell	PCW_13-14-Epithelial-Epithelial_neuroendo-epi_NE_progenitor_(7)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.26e-04	191	37	3	63aa671837b79d2feb7ed1e67712cc01caf72bef
ToppCell	COPD-Epithelial-Club\|COPD / Disease state, Lineage and Cell class	ZNF608 KIAA1217 ESRP1	5.26e-04	191	37	3	c909cf5fa0e6519aa93a47d2c3fcd2ae2163cd8d
ToppCell	severe_COVID-19-CD4+_Tcm\|severe_COVID-19 / disease group, cell group and cell class (v2)	TC2N SC5D DDX24	5.26e-04	191	37	3	1ec86eaf90411ed200dbf51ae0cb5ed8060a7ec7
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_secretory_(0)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.26e-04	191	37	3	60ff989fe99d243a3d52955223680cdd1f1917a4
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ZNRF3 P3H2 ESRP1	5.26e-04	191	37	3	a0332a4ef629510fb313ec119195c44a3f704a80
ToppCell	IPF-Epithelial-Club\|World / Disease state, Lineage and Cell class	ZNF608 KIAA1217 ESRP1	5.26e-04	191	37	3	3c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	ZNRF3 P3H2 ESRP1	5.26e-04	191	37	3	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	LPS_only-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DYSF ZNF608 KIAA1217	5.26e-04	191	37	3	a7b18bcf27c38ad2353c239ecb309c80f3ef3359
ToppCell	PCW_07-8.5-Epithelial-Epithelial_proliferating-epi_proliferating3_(5)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	d3634574b2e8d2ded6446969361b70761b331aea
ToppCell	Adult-Epithelial\|Adult / Lineage, Cell type, age group and donor	P3H2 KIAA1217 ESRP1	5.34e-04	192	37	3	efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCell	COVID-19-lung-Secretory\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ZNF608 KIAA1217 ESRP1	5.34e-04	192	37	3	59261098ccb52306f837f632ebaea45b90ad30fe
ToppCell	PCW_13-14-Epithelial-Epithelial_airway-epi_intermediate_(1)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	b73f24d1c55dfef1eb01c26da117dbf637ea080a
ToppCell	Control-Epithelial-Club\|Control / Disease state, Lineage and Cell class	ZNF608 KIAA1217 ESRP1	5.34e-04	192	37	3	d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16
ToppCell	PCW_10-12-Epithelial-Epithelial_alveolar-distal-epi_CTGF^high_distal_(3)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	39804d9ddc67c1b41887752df2503389eae44a1a
ToppCell	PCW_13-14-Epithelial-Epithelial_proliferating-epi_proliferating1_(8)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	8898332387e5d746feb346ce1dabd6b2218fc6e5
ToppCell	Epithelial-alveolar_epithelial_cell_type_2\|World / Lineage, Cell type, age group and donor	ZNRF3 P3H2 ESRP1	5.34e-04	192	37	3	58c3737be7acce39fd2b91d70d6d7b2bbaa4f710
ToppCell	PCW_07-8.5-Epithelial-Epithelial_proliferating\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	1aa5e4d9b32013a3f272561dcb8377f6805706df
ToppCell	PCW_05-06-Epithelial-Epithelial_airway-epi_proximal_progenitor2_(4)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.34e-04	192	37	3	c15841f35e24d6ef6ce2a9a6dc62e66efdc3d9d5
ToppCell	PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_CTGF^high_distal_(3)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TC2N P3H2 ESRP1	5.42e-04	193	37	3	ab78fb1603ea6f720ba2d30148fe65dccf271fe1
Drug	3-phenyllactic acid	CPA4 CPA6 EXT2 HMGCR	4.66e-07	39	37	4	CID000003848
Drug	SR 142948	NTSR2 NTSR1	1.54e-05	4	37	2	ctd:C114947
Drug	5,5-dimethylhexanoate	CPA4 CPA6	2.56e-05	5	37	2	CID003015183
Drug	neurotensin 69L	NTSR2 NTSR1	2.56e-05	5	37	2	ctd:C407426
Drug	2-phenylethanesulfonate	CPA4 CPA6	2.56e-05	5	37	2	CID000417606
Drug	Tu X	CPA4 CPA6	2.56e-05	5	37	2	CID000449223
Drug	adamantane-2-carboxylic acid	NTSR2 NTSR1	2.56e-05	5	37	2	CID000303802
Drug	Neurotensin (1-6)	NTSR2 NTSR1	3.84e-05	6	37	2	CID000137323
Drug	NSC-333758	CPA4 CPA6	3.84e-05	6	37	2	CID000100086
Drug	S)-alpha-benzylmalic acid	CPA4 CPA6	3.84e-05	6	37	2	CID003050318
Drug	5-benzamido-2-benzyl-4-oxopentanoic acid	CPA4 CPA6	3.84e-05	6	37	2	CID000127893
Drug	AC1L9R5V	CPA4 CPA6	3.84e-05	6	37	2	CID000453753
Drug	BAPACPL	CPA4 CPA6	3.84e-05	6	37	2	CID006439357
Drug	BACPL	CPA4 CPA6	3.84e-05	6	37	2	CID006439356
Drug	2-benzyl-4-oxobutanoic acid	CPA4 CPA6	3.84e-05	6	37	2	CID000124534
Drug	Dakh peptide	CPA4 CPA6	3.84e-05	6	37	2	CID003083120
Drug	ochratoxin B methyl ester	CPA4 CPA6	3.84e-05	6	37	2	CID000609664
Drug	benzoylglycylphenyllactate	CPA4 CPA6	3.84e-05	6	37	2	CID000151136
Drug	Jmv 449	NTSR2 NTSR1	3.84e-05	6	37	2	CID000164415
Drug	2-benzyl-3-phosphonopropionic acid	CPA4 CPA6	3.84e-05	6	37	2	CID000127415
Drug	2-benzyl-3-iodo-propanoic acid	CPA4 CPA6	3.84e-05	6	37	2	CID000001542
Drug	ClCH2CO-DL-(N-OH)Leu-OCH3	CPA4 CPA6	3.84e-05	6	37	2	CID000191880
Drug	2-ethyl-2-methylsuccinic acid	CPA4 CPA6	3.84e-05	6	37	2	CID000097776
Drug	3,10-dimethyl-5-deazaisoalloxazine	CPA4 CPA6	3.84e-05	6	37	2	CID000100264
Drug	AC1L5GYK	CPA4 CPA6	3.84e-05	6	37	2	CID000275083
Drug	beta-dolabrin	CPA4 CPA6	5.37e-05	7	37	2	CID000188981
Drug	Nt69l	NTSR2 NTSR1	5.37e-05	7	37	2	CID005311319
Drug	gamma-thujaplicin	CPA4 CPA6	5.37e-05	7	37	2	CID000012649
Drug	phenylpropynal	CPA4 CPA6	5.37e-05	7	37	2	CID000075740
Drug	NSC89642	CPA4 CPA6	5.37e-05	7	37	2	CID000070889
Drug	SQ24798	CPA4 CPA6	5.37e-05	7	37	2	CID000194328
Drug	hippurylglycine	CPA4 CPA6	5.37e-05	7	37	2	CID000096770
Drug	L024104	NTSR2 SI NTSR1	6.50e-05	48	37	3	CID003025353
Drug	Boc-ca-phe	CPA4 CPA6	7.15e-05	8	37	2	CID005487215
Drug	SQ 14,603	CPA4 CPA6	7.15e-05	8	37	2	CID000194327
Drug	AC1NUP4F	CPA4 CPA6	7.15e-05	8	37	2	CID005487101
Drug	hippuryl-L-phenylalanine	CPA4 CPA6	7.15e-05	8	37	2	CID000098154
Drug	bromoacetyl-D-arginine	CPA4 CPA6	7.15e-05	8	37	2	CID003082329
Drug	AC1NUT0W	CPA4 CPA6	7.15e-05	8	37	2	CID005492256
Drug	Neurotensin	NTSR2 NTSR1	7.15e-05	8	37	2	ctd:D009496
Drug	Z-ca-gly-phe	CPA4 CPA6	7.15e-05	8	37	2	CID000195338
Drug	Muracein A	CPA4 CPA6	9.18e-05	9	37	2	CID005491013
Drug	MTX-Ala	CPA4 CPA6	9.18e-05	9	37	2	CID005489429
Drug	SR142948A	NTSR2 NTSR1	9.18e-05	9	37	2	CID005311451
Drug	MTX-Arg	CPA4 CPA6	1.15e-04	10	37	2	CID000131128
Drug	ziprasidone	HMGCR SC5D	1.15e-04	10	37	2	ctd:C092292
Drug	Tyrosine-4-azobenzenearsonate	CPA4 CPA6	1.15e-04	10	37	2	CID009577326
Drug	Pareptide	CPA4 CPA6	1.15e-04	10	37	2	CID010086055
Drug	glutamate thiol	CPA4 CPA6	1.15e-04	10	37	2	CID000125415
Drug	m169	CPA4 CPA6	1.40e-04	11	37	2	CID000010946
Drug	Dns-gltaptv	CPA4 CPA6	1.40e-04	11	37	2	CID005487274
Drug	tetrazol-5-imine	CPA4 CPA6	1.40e-04	11	37	2	CID000407223
Drug	benzyl sulfonate	CPA4 CPA6	1.40e-04	11	37	2	CID000007532
Drug	archazolid B	CPA4 HMGCR SC5D	1.61e-04	65	37	3	ctd:C519728
Drug	Neurotensin (1-8)	NTSR2 NTSR1	1.68e-04	12	37	2	CID000196178
Drug	pie-like	CPA4 CPA6	1.98e-04	13	37	2	CID000017384
Drug	ochratoxin alpha	CPA4 CPA6	1.98e-04	13	37	2	CID000107911
Drug	2-amino-4-methyl-1-pentanethiol	CPA4 CPA6	1.98e-04	13	37	2	CID000003861
Drug	hydroxyl radicals	CPA4 CPA6 SI HMGCR HSD11B1 ARSF SC5D MYCBP2 ARSG	2.30e-04	1341	37	9	CID000000961
Drug	N-Q-I	CPA4 CPA6	2.31e-04	14	37	2	CID015942689
Drug	beta-isopropyl-tropolone	CPA4 CPA6	2.31e-04	14	37	2	CID000080297
Drug	AC1Q5JOY	NTSR2 NTSR1	2.31e-04	14	37	2	CID000123783
Drug	Tyr-D-Ala-Phe-Phe-NH2	CPA4 CPA6	2.31e-04	14	37	2	CID004584008
Drug	M 603	CPA4 CPA6	2.66e-04	15	37	2	CID000162977
Drug	phenylethylaminoalanine	CPA4 CPA6	2.66e-04	15	37	2	CID000133429
Drug	AC1MOX0W	CPA4 CPA6	2.66e-04	15	37	2	CID003402113
Drug	procyanidin B-5 3,3'-di-O-gallate	CPA4 CPA6	2.66e-04	15	37	2	CID003086518
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HG-U133A	SAV1 CHKA SC5D SS18	2.76e-04	195	37	4	421_UP
Drug	dibenzyl succinate	CPA4 CPA6	3.04e-04	16	37	2	CID000007653
Drug	hippuryl-L-lysine	CPA4 CPA6	3.44e-04	17	37	2	CID000098208
Drug	NL63	CPA4 CPA6	5.29e-04	21	37	2	CID011845757
Drug	Rpch	CPA4 CPA6	5.29e-04	21	37	2	CID000123998
Drug	Z-Gly	CPA4 CPA6	5.82e-04	22	37	2	CID000014349
Drug	2'-Monophosphoadenosine 5'-Diphosphoribose	HMGCR HSD11B1	6.36e-04	23	37	2	DB03461
Drug	arsanilic acid	CPA4 CPA6	6.36e-04	23	37	2	CID000007389
Drug	citraconic anhydride	CPA6 SI	6.93e-04	24	37	2	CID000012012
Drug	hippuryl-L-arginine	CPA4 CPA6	7.53e-04	25	37	2	CID000096815
Drug	pinolenic acid	HMGCR DGAT1	7.53e-04	25	37	2	CID005312493
Drug	difenoconazole	HMGCR SC5D	7.53e-04	25	37	2	ctd:C115058
Drug	cyclen	CPA4 CPA6	7.53e-04	25	37	2	CID000064963
Drug	CAS 79547-78-7	NTSR2 NTSR1	7.53e-04	25	37	2	CID000003915
Drug	hippuryl-histidyl-leucine	CPA4 CPA6	8.15e-04	26	37	2	CID000094418
Drug	glycyl-l-tyrosine	CPA4 CPA6	8.15e-04	26	37	2	CID000092829
Drug	lysinoalanine	CPA4 CPA6	8.15e-04	26	37	2	CID000029269
Drug	AC1MRI6N	CPA4 CPA6	8.79e-04	27	37	2	CID000417447
Drug	AO-128	SAV1 SI	1.01e-03	29	37	2	CID000005677
Drug	Lupex	CPA6 CHKA TRHR	1.07e-03	124	37	3	CID000042785
Drug	Evans blue dye	NTSR2 DYSF NTSR1	1.15e-03	127	37	3	CID005356750
Drug	K-13	CPA4 CPA6	1.16e-03	31	37	2	CID000469669
Drug	SR 48692	NTSR2 NTSR1	1.24e-03	32	37	2	CID000119192
Drug	guanidinoethylmercaptosuccinic acid	CPA4 CPA6	1.48e-03	35	37	2	CID000003464
Drug	DL-penicillamine	CPA4 CPA6 P3H2	1.49e-03	139	37	3	CID000004727
Drug	NSC9567	CPA6 HSD11B1 NTSR1	1.55e-03	141	37	3	CID000003001
Disease	Adrenocortical carcinoma	ZNRF3 MEN1	2.07e-04	18	35	2	C0206686
Disease	chronic kidney disease (biomarker_via_orthology)	HMGCR DGAT1	5.07e-04	28	35	2	DOID:784 (biomarker_via_orthology)

Protein segments in the cluster

Peptide	Gene	Start	Entry
CHHPYNYGFDYYYGM	ARSF	151	P54793
NYGFDYYYGMPFTLV	ARSF	156	P54793
RGFDYYFGIPYSHDM	ARSG	151	Q96EG1
MAYYYYSANEEFRPE	HSD11B1	16	P28845
MYVHDYYVLNYEAPA	DGAT1	471	O75907
QYYRPLHDEYCFYNG	DENND3	81	A2RUS2
YFYIMPVFNVDGYHF	CPA6	231	Q8N4T0
YPAGTQLFMNYTAYY	ESRP1	591	Q6NXG1
TYYRDEHIYPYMYLA	MEN1	316	O00255
YNMVPSIEPYGYFYH	OVOS1	551	Q6IE37
LDYGFQRDYYDGMYS	HNRNPCL1	111	O60812
LDYGFQRDYYDGMYS	HNRNPCL2	111	B2RXH8
PFLYDFYHYFYMVTN	NTSR1	336	P30989
PLYNFYHYFYMVTNT	NTSR2	331	O95665
YLPYRDYNYSLVMGA	HMGCR	511	P04035
CLPENYQMKYYFYHG	NAA10	21	P41227
GHYDYYYAQLDMLRR	NEK5	356	Q6P3R8
YYGQHFVPLDYFYQL	CSNKA2IP	6	A0A1B0GTH6
MDRDSYHHYFYDYDG	MYCLP1	1	P12525
FYGAAMYTYVLPHSY	OR2T27	251	Q8NH04
PLHYDYLQFAYYRVG	P3H2	306	Q8IVL5
GESMYYNDAYGALDY	RBM4B	206	Q9BQ04
FYGAAIYNYMLPSSY	OR2T10	251	Q8NGZ9
DYMLDHPEEYYSHYY	DNAJC25	121	Q9H1X3
MYDYSYEKYPFFRAN	CHKA	351	P35790
GYMDYAQARFDAYFH	CHKA	436	P35790
DLHSYSQLLMYPYGY	CPA4	306	Q9UI42
PYEDFMYRHLQYYGY	AGBL2	16	Q5U5Z8
DFYLYYFLMQYPGRS	DDX24	576	Q9GZR7
FDYGNRYHLRCYMYQ	DYSF	1146	O75923
NYYSPIYLMDFGVFY	TRHR	186	P34981
GPSYDVYNPFYMYQH	TC2N	121	Q8N9U0
MYRNEGFYADPYLYH	KIAA1217	386	Q5T5P2
PAGYAMNRYAYYVCY	MYCBP2	4531	O75592
GYKLNSYGFHPYYMA	SI	1141	P14410
YRYYEYNHDLFQRMP	SAV1	156	Q9H4B6
MNQQYYPDGHNDYGY	SS18	286	Q15532
HKYFNYLYTYKMPGD	EXT2	601	Q93063
QSLYYGQYAYGLYMD	ZNF608	1076	Q9ULD9
SYIQYLHAYPYPQMY	ZNF608	1341	Q9ULD9
ETMYQHYYFQGLSYP	ZNRF3	466	Q9ULT6
DHHMFFDYNYGQYFT	SC5D	231	O75845